Research output per year
Research output per year
Fingerprint
Dive into the research topics where Signe Christensen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Bivirkninger til kræftbehandling: Kemoterapi
Eskesen, M. H., Zickert, J. & Christensen, S., Aug 2025, In: Månedsskrift for Almen Praksis. 102, 8, p. 480-485 6 p.Research output: Contribution to journal › Journal article › Communication
-
PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer
Shim, S., Reinacher-Schick, A., Kraeft, A. L., Pfeiffer, P., Tarpgaard, L. S., Ettrich, T. J., Kestler, A., Christensen, S., Jandu, H., Nawabi, M., Roest, N. L., Damstrup, L., Vestlev, P. M., Brünner, N., Stenvang, J. & Ladekarl, M., 24 Apr 2025, In: Investigational New Drugs. 43, 2, p. 337-347 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile4 Link opens in a new tab Citations (Scopus)57 Downloads (Pure) -
Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients
Flak, R. V., Kofod-Olsen, E., Sølvsten, N. D., Naujokaite, G., Agger, R., Stender, M. T., Christensen, S., Shim, S., Poulsen, L. Ø., Detlefsen, S., Thorlasius-Ussing, O. & Ladekarl, M., 18 Oct 2024, In: iScience. 27, 10, 19 p., 111026.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile75 Downloads (Pure) -
Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients – a randomized controlled trial. (OxaNeuro)
Gehr, N. L., Karlsson, P., Timm, S., Christensen, S., Hvid, C. A., Peric, J., Hansen, T. F., Lauritzen, L., Finnerup, N. B. & Ventzel, L., 3 Feb 2024, In: BMC Cancer. 24, 1, 10 p., 168 .Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile7 Link opens in a new tab Citations (Scopus)106 Downloads (Pure) -
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
Rasmussen, L. S., Winther, S. B., M. Chen, I., Weber, B., Ventzel, L., Liposits, G., Johansen, J. S., Detlefsen, S., Egendal, I., Shim, S., Christensen, S., Pfeiffer, P. & Ladekarl, M., 16 Jun 2023, In: BMC Cancer. 23, 1, 552.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile3 Link opens in a new tab Citations (Scopus)130 Downloads (Pure)
Datasets
-
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
Rasmussen, L. S. (Creator), Winther, S. B. (Creator), Chen, I. M. (Creator), Weber, B. (Creator), Ventzel, L. (Creator), Liposits, G. (Creator), Johansen, J. S. (Creator), Detlefsen, S. (Creator), Egendal, I. (Creator), Shim, S. (Creator), Christensen, S. (Creator), Pfeiffer, P. (Creator) & Ladekarl, M. (Creator), Figshare, 2024
DOI: 10.6084/m9.figshare.c.6701001.v1, https://springernature.figshare.com/collections/A_randomized_phase_II_study_of_full_dose_gemcitabine_versus_reduced_dose_gemcitabine_and_nab-paclitaxel_in_vulnerable_patients_with_non-resectable_pancreatic_cancer_DPCG-01_/6701001/1
Dataset: Supplementary material